A Senate hearing exchange focused on FDA regulatory flexibility for rare-disease treatments (including ALS), assurances about vaccine advisory committee meetings, and questions about proposed FDA funding cuts for state and local food-safety inspections and potential impacts on Alaska's seafood industry.